



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1614
RECEIVED

JUL 05 2001

TECH CENTER 1600/2900

ATTY.'S DOCKET: KAASTRUP1A

In re Application of:

Peter KAASTRUP

Serial No.: 09/822,873

Filed: April 2, 2001

For: VACCINE CHIP TECHNOLOGY
EXPLOITING
IMMUNOSTIMULATING...

) Art Unit: 1614

) Examiner:

) Confirmation No. 7206

) Washington D.C.

) July 2, 2001

#5

BEST AVAILABLE COPY

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

S i r :

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed:

[XX] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application. See 37 CFR 1.97(b).

[] B. before the mailing date of a first office action on the merits. See 37 CFR 1.97(b).

[] C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary certification (box "i" below) or paid the necessary fee (box "ii" below). See 37 CFR 1.97(c).

[] i. Counsel certifies that, upon information and belief, each item of information listed herein was either (a) cited in a communication from a foreign

patent office in a counterpart foreign application not more than three months prior to the filing of this IDS or (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.

[] ii. A check for the fee set forth in 1.17(p), presently believed to be \$180, is enclosed (check no. _____).

[] D. after (A), (B) and (C) above, but before payment of the issue fee. Applicant petitions under 37 C.F.R. 1.97(d) for consideration of this IDS. A check for the fee set forth in 1.17(i)(1), presently believed to be \$130 is enclosed (check no. _____). Counsel certifies that, upon information and belief, each item of information listed herein was either (i) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS or (ii) was not cited in a communication from a foreign patent office in a counterpart foreign application and was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.

[] E. As a submission in accordance with the transitional procedure for limited examination after final rejection pursuant to 37 CFR §1.129(a). Pursuant to MPEP §706.07(g), page 700-46, col. 2 (February 2000), this IDS is treated as if filed with a period set forth in 37 CFR §1.97(b) and considered without the petition and petition fee required by 1.97(d).

2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document is attached, except

as explained below.

While an IDS filed under §1.97 must contain a "list of all patents, publications or other information submitted for consideration by the Office", see §1.98(a) (1), the only requirement for the list is that it provide the information set forth in §1.98(b). There is no requirement that a form PTO-1449 be used (MPEP §609 merely says that use of this form is "encouraged"). Counsel has used a list provided to him by Applicants, and not transferred the information to a PTO-1449, to avoid the risk of any inadvertent error in transferring the information.

☐ 3. Documents _____ are not in the English language. In accordance with 1.98(c), Applicants state:

☐ documents _____ already contain an English language abstract, summary or claim set.

☐ a publicly available abstract is attached to each of documents _____, and the source of each abstract is indicated thereon.

☐ documents _____ are patents or published patent applications for which counterpart English language patents or patent applications exist, and are enclosed, as follows:

<u>Foreign Lang. Doc.#</u>	<u>English Lang. Doc.#</u>
[insert]	[insert]

☐ applicants have prepared an English translation of at least the pertinent portions of documents _____, and copies are attached.

☐ A concise explanation of the relevance of documents _____ is found in the attached search report from the _____ Patent Office (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).

☐ A concise explanation of the relevance of documents _____ is set forth as follows:
[Insert concise explanation of relevance]

In re Appl. No. 09/822,873

4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

5. Other information being provided for the examiner's consideration follows:

[insert other information]

6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

7. The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: 

Iver P. Cooper
Reg. No. 28,005


624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
IPC:nmp
F:\,H\hoib\Kaastrup1A\Pto\ids.wpd



Prior art references for Information Disclosure Statement

Docket No.: KAASTRUP1A
Serial No. 09/822,873
Confirmation No. 7206
Filing Date: April 2, 2001

1. US 4,774,332; Seyedin et al.; September 27, 1988
2. US 4,886,747; Derynck et al.; December 12, 1989
3. US 4,894,332; Schaller et al.; January 16, 1990
4. US 5,019,384; Gefter et al.; May 28, 1991
5. US 5,061,786; Burnier et al.; October 29, 1991
6. US 5,116,943; Koths et al.; May 26, 1992
7. US 5,118,791; Burnier et al.; June 2, 1992
8. US 5,194,254; Barber et al.; March 16, 1993
9. US 5,268,455; Cianciolo; December 7, 1993
10. US 5,453,492; Butzow et al.; September 26, 1995
11. US 5,554,372; Hunter; September 10, 1996
12. US 5,583,109; Clark et al.; December 10, 1996
13. US 5,589,384; Lipscombe et al.; December 31, 1996
14. US 5,603,933; Dwyer IV et al.; February 18, 1997
15. US 5,738,852; Robinson et al.; April 14, 1998
16. US 5,772,995; Fakhrai et al.; June 30, 1998
17. US 5,837,269; Daynes et al.; November 17, 1998
18. US 5,843,446; Ladd et al.; December 1, 1998
19. US 5,864,027; Berman et al.; January 26, 1999
20. US 5,874,085; Mond et al.; February 23, 1999



Prior art references for Information Disclosure Statement

Docket No.: KAASTRUP1A
Serial No. 09/822,873
Confirmation No. 7206
Filing Date: April 2, 2001


21. US 5,876,735; Reed; March 2, 1999
22. US 5,900,238; Gombotz et al.; May 4, 1999
23. US 5,904,920; Dranoff et al.; May 18, 1999
24. US 5,961,979; Srivastava; October 5, 1999
25. US 5,972,655; Marcu; October 26, 1999
26. US 5,976,541; Berzofsky et al.; November 2, 1999
27. US 5,980,899; Berzofsky et al.; November 9, 1999
28. US 5,980,913; Penney; November 9, 1999
29. US 6,013,268; Reed; January 11, 2000
30. US 6,013,478; Wells et al.; January 11, 2000
31. US 6,015,694; Dubensky Jr. et al.; January 18, 2000
32. US 6,171,584; Hotten et al.; January 9, 2001
33. WO 88/05787; Lucas et al.; august 11, 1988
34. WO 88/05788; Lucas et al.; August 11, 1988
35. WO 90/14359; Burnier et al.; November 29, 1990
36. WO 90/14360; Iwata et al.; November 29, 1990
37. WO 91/04748; Border et al.; April 18, 1991
38. WO 91/05565; Cohen et al.; May 2, 1991
39. WO 94/17099; Ogawa et al.; August 4, 1994



Prior art references for Information Disclosure Statement

Docket No.: KAASTRUP1A
Serial No. 09/822,873
Confirmation No. 7206
Filing Date: April 2, 2001

40. WO 96/30038; Hemmati-Brivanlou et al.; October 3, 1996
41. WO 96/36349; Khalil et al.; November 21, 1996
42. EP 0290012 A1; Marquardt et al.; Novemer 9, 1988
43. A.J.M. Van den Eijenden-Van Raaij, I. Koorneef, H.G. Slager, C.L. Mummery and E.J.J. Zoelen. (1990) Charaterization of polyclonal anti-peptide antibodies specific for transforming growth factor β_2 . *Journal of Immunological Methods* 133: 107-118
44. Yi Jin, David A. Cox, et al. (1991) Separation, Purification and Sequence Identification of TGF- β_1 and TGF- β_2 from Bovine Milk. *Journal of Protein Chemistry* 10: 565-575
45. Wieczorek et al. (1995) The immunomodulatory diversity of the proteins of the transforming growth factor β (TGF β) family. *Int. J. Peptide Protein Res.* 46: 113-118
46. Schiött et al. (1999) Transforming growth factor- β_1 , a strong costimulator of rat T-cell activation promoting a shift towards a Th2-like cytokine profile. *Immunology Letters* 67: 131-139
47. Abstract of Skundric et al. (1997) Immunostimulatory effect og TGF β is downregulated by growth factor treatment of Schwann cells. *Journal of Neurochemistry* 70: 32
48. Fundamental immunology, 4th edition, editor: Wiiliam E. Paul. (1998) Lippincott-Raves Publishers. P. 638-639, 648-649, 800-803, 810-811, 838-839, 854-859, 878-908, 1304-1305 and 1328-1329.
49. Flanders, Roberts, Ling, Fleurdelys and Sporn. (1988) Antibodies to peptide determinants in transforming growth factor β and their applications. *Biochemistry* 27: 739-746.



Prior art references for Information Disclosure Statement

Docket No.: KAASTRUP1A
Serial No. 09/822,873
Confirmation No. 7206
Filing Date: April 2, 2001

50. Schiött, Sjögren and Lindvall. (1998) The three isoforms of transforming growth factor- β Co-stimulate Rat T cells and inhibit Lymphocyte Apoptosis. *Scand. J. Immunol* 48: 371-378
51. Abstract of Jackson, Ronald H. (1998) Modulation of the activity of transforming growth factor beta. *Expert Opin. Ther. Pat.* 8: 1479-1486
52. Abstract of Thompson JE et al. (1999) A fully human neutralising biologically active human TGF- β 2 for use in therapy. *J. Immunol Methods* 227: 17-29
53. Abstract of Huang, et al. (1997) Transforming growth factor β peptide antagonists and their conversion to partial agonists. *J. Biol. Chem.* 272: 27155-27159
54. Partidos et al. (1999) Heat-labile enterotoxin of *Escherichia coli* and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides. *Immunology Letters* 67: 209-216
55. Partidos et al. (1997) CTL responses induced by a single immunization with peptide encapsulated in biodegradable microparticles. *Journal of Immunological Methods* 206: 143-151
56. Tochikubo et al. (1998) Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemetic responses of mice to mucosally co-administrated bovine serum albumin. *Vaccine* 16: 150-155
57. Partidos and Kanse. (1997) Specificity of the T-cell responses in covalently linked peptides each comprising of a T helper epitope. *Molecular Immunology* 34: 1105-1111
58. Partidos et al. (1996) The adjuvant effect of a non-toxic mutant og heat-labile enteroxotin of *Escherchia Coli* for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide. *Immunology* 89: 483-487



— Prior art references for Information Disclosure Statement

Docket No.: KAASTRUP1A
Serial No. 09/822,873
Confirmation No. 7206
Filing Date: April 2, 2001

59. Bellone et al. (1994) Preferential pairing of T and B cells for production of antibodies without covalent association of T and B cells. *Eur. J. Immunol.* 24: 799-804
60. Giuseppe Del Giudice (1992) New carriers and adjuvants in the development of vaccines. *Current Opinion in Immunology* 4: 454-459
61. Bennett et al. (1992) A comparison of commercially available adjuvants for use in research. *Journal of Immunological Methods* 153: 31-40
62. Sarobe et al. (1991) Induction of antibodies against a peptide hapten does not require covalent linkage between the hapten and a class II presentable T helper peptide. *Eur. J. Immunol.* 21: 1555-1558
63. Partidos et al. (1992) Antibody responses to non-immunogenic synthetic peptides induced by co-immunization with immunogenic peptides. *Immunology* 77: 262-266